About Carboxypeptidase A4
Carboxypeptidase A4 (CPA4) is a protein
from Homo sapiens identified by UniProt accession
Q9UI42, 421 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | Carboxypeptidase A4 |
|---|
| UniProt accession | Q9UI42 |
|---|
| Gene | CPA4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 421 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (51)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.27
- rheumatoid arthritis · score 0.15
- Immature Reticulocyte Fraction Measurement · score 0.11
- non-small cell lung carcinoma · score 0.10
- reticulocyte count · score 0.09
- bladder transitional cell carcinoma · score 0.08
- triple-negative breast cancer · score 0.08
- pachyonychia congenita · score 0.07
- colorectal carcinoma · score 0.07
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UI42-F1 | alphafold | PREDICTED | 93.71 | — |
Amino-acid sequence (421 residues)
MRWILFIGAL IGSSICGQEK FFGDQVLRIN VRNGDEISKL SQLVNSNNLK LNFWKSPSSF NRPVDVLVPS VSLQAFKSFL RSQGLEYAVT IEDLQALLDN EDDEMQHNEG QERSSNNFNY GAYHSLEAIY HEMDNIAADF PDLARRVKIG HSFENRPMYV LKFSTGKGVR RPAVWLNAGI HSREWISQAT AIWTARKIVS DYQRDPAITS ILEKMDIFLL PVANPDGYVY TQTQNRLWRK TRSRNPGSSC IGADPNRNWN ASFAGKGASD NPCSEVYHGP HANSEVEVKS VVDFIQKHGN FKGFIDLHSY SQLLMYPYGY SVKKAPDAEE LDKVARLAAK ALASVSGTEY QVGPTCTTVY PASGSSIDWA YDNGIKFAFT FELRDTGTYG FLLPANQIIP TAEETWLGLK TIMEHVRDNL Y
Explore Carboxypeptidase A4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets